Sfoglia per Autore
Re: randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma
2000 P. Pedrazzoli, A.S. Bianchi, M. Renga, S. Siena
Optimal CD34+ cell dose in autologous peripheral-blood stem-cell transplantation [2] (multiple letters)
2000 O. Sezer, K. Possinger, B. Metzner, H.-. Illiger, M. Wattad, W. Heit, H. Fuss, W. Schultze, S. Siena, R. Schiavo, A. Sartore-Bianchi, P. Pedrazzoli
Controversies in the management of brain metastases: the role of chemotherapy
2001 G. Landonio, A. Sartore-Bianchi, L. Giannetta, M. Renga, M. Riva, S. Siena
Meningeal carcinomatosis in rectal cancer
2002 A. Sartore-Bianchi, P. Pedrazzoli, L. Ponchio, A. Lanza, L. Pavesi
Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?
2002 C. Porta, V. Rizzo, M. Zimatore, A. Sartore-Bianchi, M. Danova, L. Mutti
Gemcitabine and Oxaliplatin in the Treatment of Patients with Immunotherapy-Resistant Advanced Renal Cell Carcinoma: Final Results of a Single-Institution Phase II Study
2004 C. Porta, M. Zimatore, I. Imarisio, A. Natalizi, A. Sartore-Bianchi, M. Danova, A. Riccardi
Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients
2004 A. Sartore-Bianchi, A. Soriani, R. Mattioni, A. Vaglio, C. Buzio, C. Porta
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
2005 M. Moroni, S. Veronese, S. Benvenuti, G. Marrapese, A. Sartore Bianchi, F. Di Nicolantonio, M. Gambacorta, S. Siena, A. Bardelli
Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer
2005 M. Moroni, A. Sartore-Bianchi, S. Benvenuti, S. Artale, A. Bardelli, S. Siena
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients
2005 C. Porta, M. Zimatore, L. Bonomi, I. Imarisio, C. Paglino, A. Sartore-Bianchi, L. Mutti
Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients
2005 C. Porta, I. Imarisio, M. De Amici, L. Bonomi, C. Paglino, E. Biscaldi, M. Zimatore, A. Sartore-Bianchi, M. Danova, R. Moratti, A. Riccardi
Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer
2006 A. Sartore Bianchi, G. Cerea, I. Schiavetto, L. Giannetta, R. Ricotta, M.R. Maugeri, M. Moroni, G. Marrapese, S. Siena
Cetuximab for treatment of metastatic colorectal cancer
2006 G. Cerea, R. Ricotta, I. Schiavetto, M.R. Maugeri, A. Sartore-Bianchi, M. Moroni, S. Artale, S. Siena
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
2007 A. Sartore Bianchi, M. Moroni, S. Veronese, C. Carnaghi, E. Bajetta, G. Luppi, A. Sobrero, C. Barone, S. Cascinu, G. Colucci, E. Cortesi, M. Nichelatti, M. Gambacorta, S. Siena
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
2007 S. Benvenuti, A. Sartore Bianchi, F. Di Nicolantonio, C. Zanon, M. Moroni, S. Veronese, S. Siena, A. Bardelli
Rationale and clinical results of multi-target treatments in oncology
2007 A. Sartore-Bianchi, R. Ricotta, G. Cerea, M.R. Maugeri, S. Siena
Bortezomib inhibits nuclear factor-κB-dependent survival and has potent in vivo activity in mesothelioma
2007 A. Sartore-Bianchi, F. Gasparri, A. Galvani, L. Nici, J.W. Darnowski, D. Barbone, D.A. Fennell, G. Gaudino, C. Porta, L. Mutti
Epidermal growth factor receptor-targeted therapy of colorectal cancer with panitumumab
2007 A. Sartore-Bianchi, A. Sporchia, G. Cerea, M.R. Maugeri, T. Cipani, I. Andreotti, G. Marrapese, S. Artale, S. Siena
Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: A case report and review of the literature
2008 M. Moroni, S. Veronese, A. Sartore-Bianchi, S. Artale, S. Siena
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
2008 F. Di Nicolantonio, M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. De Dosso, L. Mazzucchelli, M. Frattini, S. Siena, A. Bardelli
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile